Bolni Marius Nagalo
Associate Professor
Also affiliated: University of Maryland, Baltimore (2025–2026); Université Joseph Ki-Zerbo (2011–2023); Mayo Clinic (2020–2022); University of Arkansas Medical Center (2023–2025); WinnMed (2020); DC Cancer Consortium (2024); Palmetto Hematology Oncology (2013); Centre National de la Recherche Scientifique et Technologique (2011); Centre Hospitalier Universitaire Yalgado Ouédraogo (2013); Centre National de Semences Forestières (2011); Mayo Clinic in Arizona (2017–2024); Mayo Clinic Hospital (2020–2024); Winthrop Rockefeller Foundation (2022–2025); Université des Sciences et Techniques de Masuku (2017–2019); Advanced Genomic Technology (United States) (2020); Mayo Clinic in Florida (2020); Center for Cancer Research (2025); UNC Lineberger Comprehensive Cancer Center (2025); University of Baltimore (2025–2026)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Bolni Marius Nagalo's research focuses on understanding and developing novel strategies for treating various cancers, particularly hepatocellular carcinoma and pancreatic cancer. His work on hepatocellular carcinoma is supported by a National Institutes of Health (NIH)/National Cancer Institute grant for investigating the cGAS-STING pathway as a therapeutic target, employing adenoviruses with specific replication controls. He also received NIH funding to explore new methods for enhancing drug delivery and tumor immunogenicity in pancreatic cancer.
Nagalo's scholarly output includes over 100 publications, with an h-index of 17 and more than 1,100 citations. His recent work has explored diverse areas such as the interaction of viral vectors with cellular components, the role of the tumor microenvironment in pancreatic cancer, and the potential of natural compounds like fisetin in alleviating inflammatory conditions. Other publications address therapeutic combinations for biliary tract cancers, cell-free tumor DNA in advanced cancers, and the prevalence of blood-borne infections among blood donors in Burkina Faso.
He leads a research group at the University of Arkansas for Medical Sciences and collaborates with several colleagues within the institution, including Steven R. Post, Mulu Z. Tesfay, Khandoker Usran Ferdous, and Martin J. Cannon, with whom he shares multiple publications. Nagalo's research contributions span cancer biology, immunology, and translational medicine.
Metrics
- h-index: 17
- Publications: 100
- Citations: 1,188
Selected Publications
-
Loss of FAM60A disrupts Sin3/HDAC control of the Hippo signaling and promotes oncogenic YAP1 activation (2026)
-
Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection (2026)
-
Prognostic factors and survival outcomes in colorectal cancer: insights from a Ghanaian cohort (2025)
-
The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer (2025)
-
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025)
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis (2025)
-
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)
-
Abstract 950: Engineered oncolytic vesiculovirus downsizes pancreatic tumor and boosts immune response (2025)
-
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)
-
Abstract 2792: PiRNA as a novel therapeutic in hepatocellular carcinoma: insights from population screening (2025)
-
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)
-
Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059) (2025)
-
474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells (2025)
-
Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma (2025)
Federal Grants 2 $229,687 total
Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer
Collaboration Network
Top Collaborators
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 12 shared publications
- Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
- Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
Showing 5 of 11 shared publications
- Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation
- Synthesis, <i>in silico</i> modelling, and <i>in vitro</i> biological evaluation of substituted pyrazole derivatives as potential anti-skin cancer, anti-tyrosinase, and antioxidant agents
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
Showing 5 of 11 shared publications
- Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma
Showing 5 of 11 shared publications
- Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 9 shared publications
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Showing 5 of 9 shared publications
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Partnership in Cancer Research (PCAR) Program Increases Medical Student Knowledge and Confidence to Perform Cancer Research
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Monensin and its derivatives increase MHC Class I and II presentations in breast cancer
Showing 5 of 9 shared publications
- Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
- Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 8 shared publications
- Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 8 shared publications
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 8 shared publications
- Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Spontaneous regression of advanced hepatocellular carcinoma following COVID-19 infection and vaccination: a case report and review of literature
- Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma
- Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus
Showing 5 of 8 shared publications
- Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Showing 5 of 8 shared publications
- Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
- Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
- Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers
Showing 5 of 7 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 588: Preclinical evaluation of novel chimeric vesiculovirus mediated expression of proteolytic enzymes targeting two major stromal components of pancreatic ductal adenocarcinoma
Showing 5 of 7 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Monensin and its derivatives increase MHC Class I and II presentations in breast cancer
- 474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells
- Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059)
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics